Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Jibacoa who wrote (24271)	3/22/2001 2:51:56 PM
From: JoeinIowa	Respond to of 29382

Bernard, Good questions.I've copied some of Monday release below. Watching them fall below 8 I just could not resist. Biotech stocks are hard to place a value on. I always try to look at whats in the pipeline and what the potential market is. If they really hit something big somebody like ELAN will take them out. So much cheaper than trying to develop your own new drugs. Joe Highlights of accomplishments in 2000 and early 2001: Doubled U.S. product sales: Launched Targretin® capsules in U.S. and secured FDA approval of and launched Targretin® gel Gained First European Product Approvals: Gained approval of Panretin® gel in Europe and received CPMP recommendation to approve Targretin capsules in Europe Added Elan Pharma International to our group of exclusive distributors, to market and distribute Ligand's five near-term oncology products in key countries in Eastern and Western Europe Reported positive Phase II clinical trial results showing Targretin capsules extended survival in patients with non-small cell lung cancer (NSCLC) Morphelan(TM) NDA filed with FDA by Elan for moderate to severe chronic pain. Ligand has U.S. marketing rights to Morphelan(TM) for the treatment of chronic pain in cancer and HIV patients. Advanced androgen agonist LGD2226 to human development track for male hypogonadism, female sexual dysfunction and osteoporosis Pfizer moved lasofoxifene into Phase III trials for osteoporosis AHP made a positive evaluation of TSE424 data in osteoporosis in preparation for initiation of Phase III trials in first half 2001; advanced WAY248 to IND track Lilly advanced three clinical candidates for diabetes and cardiovascular disease Bristol-Myers Squibb entered into collaboration with Ligand to discover and develop drugs to treat congestive heart failure, hypertension and other cardiovascular diseases Organon launched collaboration with Ligand to discover and develop drugs to address hormone replacement therapy, contraception and reproductive disorders